Pfizer (PFE) Competitors

Pfizer (NYSE:PFE) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Do institutionals & insiders hold more shares of PFE or AMGN?

68.4% of Pfizer shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.1% of Pfizer shares are held by company insiders. Comparatively, 0.7% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Is PFE or AMGN a better dividend stock?

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.8%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Pfizer pays out 124.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen pays out 86.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has raised its dividend for 16 consecutive years and Amgen has raised its dividend for 14 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Does the media refer more to PFE or AMGN?

In the previous week, Pfizer had 58 more articles in the media than Amgen. MarketBeat recorded 114 mentions for Pfizer and 56 mentions for Amgen. Amgen's average media sentiment score of 1.54 beat Pfizer's score of 0.73 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	51 Very Positive mention(s)	12 Positive mention(s)	33 Neutral mention(s)	5 Negative mention(s)	9 Very Negative mention(s)	Positive
Amgen	50 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do analysts prefer PFE or AMGN?

Pfizer presently has a consensus price target of $28.55, suggesting a potential upside of 12.60%. Amgen has a consensus price target of $307.82, suggesting a potential upside of 3.63%. Given Pfizer's stronger consensus rating and higher probable upside, analysts clearly believe Pfizer is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	1 Sell rating(s)	13 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.45
Amgen	2 Sell rating(s)	12 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.35

Which has higher valuation and earnings, PFE or AMGN?

Pfizer has higher revenue and earnings than Amgen. Pfizer is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.46B	2.31	$8.03B	$1.38	18.37
Amgen	$33.42B	4.78	$4.09B	$10.96	27.10

Which has more volatility and risk, PFE or AMGN?

Pfizer has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500.

Is PFE or AMGN more profitable?

Amgen has a net margin of 17.39% compared to Pfizer's net margin of 12.62%. Amgen's return on equity of 176.11% beat Pfizer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	12.62%	20.33%	8.53%
Amgen	17.39%	176.11%	12.39%

Summary

Amgen beats Pfizer on 11 of the 20 factors compared between the two stocks.